/ CompletedNot Applicable A 12-Month Noninterventional, Postmarketing, Multicenter Study to Evaluate the Effectiveness of Briviact® (Brivaracetam) as Adjunctive Therapy in Patients With Epilepsy With Partial-onset Seizures in Daily Clinical Practice
Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard clinical practice.
100 Clinical Results associated with Icon Clinical (UK) Ltd.
0 Patents (Medical) associated with Icon Clinical (UK) Ltd.
100 Deals associated with Icon Clinical (UK) Ltd.
100 Translational Medicine associated with Icon Clinical (UK) Ltd.